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The essential amino acid tryptophan (Trp) is degraded through 
the kynurenine pathway (Figure 1), giving rise to metabolites 
referred to as kynurenines.1 The kynurenine pathway is most 
highly expressed not only in liver and monocytes2 but also in 
muscle, brain, and intestine.3 The kynurenines and the rate-
limiting enzyme indoleamine 2,3-dioxygenase (IDO) of the 
kynurenine pathway have been implicated in experimental 
cognitive dysfunction in mice,4-7 and kynurenines are lower in 
Alzheimer’s disease (AD) compared with healthy controls.8
Tryptophan 2,3-dioxygenase (TDO) and IDO generate 
kynurenine (Kyn) from Trp,9 which gives rise to downstream 
metabolites that have shown neuroprotective (kynurenic acid 
[KA])10 and neurotoxic properties (quinolinic acid [QA]).11 
Both KA and QA act as antagonist and agonist, respectively, 
at the N-methyl-d-aspartate receptor (NMDAR), suggest-
ing a potential role of kynurenines in relation to signal trans-
duction pathways related to cognitive dysfunction.12 The key 
enzymes IDO and kynurenine 3-monooxygenase (KMO) are 
induced by pro-inflammatory cytokines. KMO converts Kyn 
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ABSTRACT
INTRoDuCTIoN: Circulating tryptophan (Trp) and its downstream metabolites, the kynurenines, are potentially neuroactive. Consequently, 
they could be associated with neuropsychiatric symptoms and cognitive prognosis in patients with dementia.
oBjeCTIve: The objective of this study was to assess associations between circulating kynurenines, cognitive prognosis, and neuropsy-
chiatric symptoms.
MeThoDS: We measured baseline serum Trp, neopterin, pyridoxal 5′-phosphate (PLP), and 9 kynurenines in 155 patients with mild demen-
tia (90 with Alzheimer’s disease, 65 with Lewy body dementia). The ratios between kynurenine and Trp and kynurenic acid (KA) to kynure-
nine (KKR) were calculated. The Mini-Mental State Examination (MMSE) and the Neuropsychiatric Inventory (NPI) were administered at 
baseline and annually over 5 years. Associations between baseline metabolite concentrations with MMSE and the NPI total score were 
assessed using a generalized structural equation model (mixed-effects multiprocess model), adjusted for age, sex, current smoking, glo-
merular filtration rate, and PLP. Post hoc associations between KKRs and individual NPI items were assessed using logistic mixed-effects 
models. False discovery rate (0.05)–adjusted P values (Q values) are reported.
ReSulTS: Kynurenine had a nonlinear quadratic relationship with the intercept of the MMSE scores over 5 years (Q < 0.05), but not with the 
slope of MMSE decline. Kynurenine was associated with a higher NPI total score over time (Q < 0.001). Post hoc, both KKR and KA were 
associated with more hallucinations (Q < 0.05).
CoNCluSIoNS: Kynurenine has a complex relationship with cognition, where both low and high levels were associated with poor cognitive 
performance. A higher KKR indicated risk for neuropsychiatric symptoms, especially hallucinations.
KeywoRDS: Kynurenines, hallucinations, neuropsychiatric symptoms, kynurenic acid, kynurenine, Alzheimer’s disease, Lewy body 
dementia
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to 3-hydroxykynurenine (HK).13 Interferon gamma (IFN-γ) 
is the most potent activator.2 Higher circulating levels of 
kynurenine metabolites are associated with depression14 and 
elevated postmortem brain levels of kynurenines, and rele-
vant enzymes have been observed in patients with psychotic 
and mood disorders.15-19 Cerebrospinal fluid (CSF) levels of 
KA were not significantly altered in patients with dementia 
with Lewy bodies (DLB) compared with controls.20 The 
kynurenine-to-tryptophan ratio (KTR) and neopterin, which 
are biomarkers of cellular immune activation, have been 
associated with reduced cognitive performance in commu-
nity-dwelling older adults.21
We aimed to assess whether the levels of circulating kynure-
nines at baseline predicted cognitive prognosis and neuropsy-




The Dementia Study of Western Norway (DemVest) is a mul-
ticenter longitudinal cohort study with annual follow-up until 
death. The study recruited 155 participants from specialist 
clinics of neurology and old-age psychiatry situated in the 
Norwegian counties Hordaland and Rogaland with available 
blood samples in a biobank. Participant recruitment during 
2005 to 2007 relied on fulfillment of the inclusion criteria: 
patients diagnosed with mild dementia for the first time and a 
minimal Mini-Mental State Examination (MMSE) score of 
20.22 Thereafter, selective recruitment of patients with either 
DLB or Parkinson disease with dementia (PDD) was under-
taken. Thus, the latter 2 patient groups are overrepresented in 
the study. Due to similar pathologies, DLB and PDD were 
classified together as LBD.
Independently, 2 physicians experienced in the diagnostic 
workup of dementia made a clinical diagnosis using the 
NINCDS-ADRDA criteria for AD (National Institute of 
Neurological and Communicative Disorders and Stroke and 
Alzheimer’s Disease and Related Disorders Association)23 and 
the revised consensus criteria for DLB (2005).24 A detailed study 
protocol has been published.22 Briefly, a physician interviewed 
the patient together with a caregiver who provided complemen-
tary information. Medical history was also obtained from elec-
tronic records and a clinical neurological examination was 
performed. In addition to a global cognitive assessment of cogni-
tion by the MMSE, and dementia severity using Clinical 
Dementia Rating, patients were assessed with a standardized 
neuropsychological test battery. In situations with diagnostic 
uncertainty, physicians discussed each case until consensus. In 
addition, after 5 years, 3 specialists in geriatrics and psychiatry 
revised the diagnoses in consensus meetings. All patients were 
followed longitudinally with annual assessments with MMSE 
and the Neuropsychiatric Inventory (NPI), mostly until death. 
Due to the progressive nature of dementia, most patients fol-
lowed over time will reach a point where they score 0 on the 
MMSE on each consecutive follow-up. This is called the floor 
effect. At this point, the MMSE can no longer measure further 
disease progression, and for a statistical model, it will look as if 
disease progression has stopped. Furthermore, variance will be 
reduced at follow-ups with many 0 scores. This will result in the 
introduction of a range of statistical biases, which are not easily 
compensated for, especially if a substantial proportion of patients 
reach a floor or ceiling effect.25 Therefore, a decision was made 
to censor the study on biomarkers after the fifth follow-up.
Postmortem studies from the full DemVest study (56 
autopsies) found that the concordance rate for a clinical diag-
nosis compared with a pathological diagnosis was 83% for AD 
and 80% for LBD.26
Some data during follow-up were missing. Most were 
observed in an intermittent pattern, meaning that the patient 
missed one appointment and later returned to the study. The 
proportion of missing measurements that was not due to death 
was small. The MMSE and NPI were assessed at the same visit 
and thus had largely corresponding missing measurements. 
Accordingly, missing measurements for the MMSE are listed. 
For the MMSE, there were no missing measurements at base-
line, 6 missing measurements at the first follow-up, 11 at the 
second follow-up, 9 at the third follow-up, 6 at the fourth 
Figure 1. The kynurenine pathway. TDO and IDO convert tryptophan to 
kynurenine (Kyn). HK (3-hydroxykynurenine) is converted to 
3-hydroxyanthranilic acid (HAA) by kynureninase (KYNU), and 
subsequently to quinolinic acid (QA), catalyzed by quinolinate 
phosphoribosyl transferase. QA is converted to nicotinamide adenosine 
dinucleotide (NAD+), the final product of the pathway. Anthranilic acid 
(AA) is produced from Kyn by KYNU. Kynurenine aminotransferases 
(KATs) generate KA from Kyn and xanthurenic acid (XA) from HK. 
Picolinic acid (PIC) is produced by spontaneous conversion of HAA. Both 
KYNU and KATs have pyridoxal 5′-phosphate (PLP) as a cofactor.9 IDO 
indicates indoleamine 2,3-dioxygenase; TDO, tryptophan 2, 
3-dioxygenase; KMO, kynurenine 3-monooxygenase; KATs, kynurenine 
aminotransferases; 3-HAO, 3-hydroxyanthranilic acid 3, 4-dioxygenase; 
Spont., spontaneous; NAD+, nicotine adenine dinucleotide; HK, 
3-hydroxykynurenine; HAA, 3-hydroxyanthranilic acid.
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follow-up, and 8 at the fifth follow-up. During the study 
period, several patients died prior to their planned follow-up. 
At the second follow-up, 15 patients had died, 34 at the third, 
55 at the fourth, and 78 at the fifth follow-up.
The Mini-Mental State Examination
The MMSE has maximum score of 30 and a minimum of 0 and 
consists of a variety of questions, grouped into 7 categories rep-
resenting different cognitive domains. The categories are orien-
tation to time, orientation to place, registration of 3 words, 
attention and calculation, recall of 3 words, language, and visual 
construction.27 A decline of 2 to 4 points is considered a reliable 
change,28 and about 3 points is also the expected annual decline.29
The Neuropsychiatric Inventory
The NPI evaluates 12 neuropsychiatric symptoms common in 
dementia: delusions, hallucinations, agitation, apathy, dyspho-
ria, anxiety, irritability, euphoria, disinhibition, motor distur-
bances, and sleep- and appetite disturbances. A caregiver 
familiar with the patient rates the severity and frequency of 
each neuropsychiatric symptom using a standardized question-
naire. A combined score for each symptom is calculated by 
multiplying the frequency by severity. The total score is deter-
mined by adding all the domain scores together.30 We used the 
NPI total score to limit the number of outcomes.
Measurement of metabolic biomarkers
Baseline levels of Trp, anthranilic acid (AA), 3-hydroxyan-
thranilic acid, HK, KA, Kyn, picolinic acid, QA, xanthurenic 
acid (XA), pyridoxal 5′-phosphate (PLP), and neopterin were 
measured using liquid chromatography-tandem mass spec-
trometry in serum samples, collected between 2005 and 2009, 
and stored at −80°C until analysis in 2018. The ratio between 
Trp and Kyn (KTR) was defined as Kyn (µM)/Trp (µM)*100 
and the kynurenic acid-to-kynurenine ratio (KKR) was esti-
mated. The limit of detection for neopterin and the kynure-
nines ranged from 0.5 to 7 nmol/L, whereas the limit of 
detection for Trp was 0.4 µmol/L. Within-day and between-
day coefficients of variation were 5.7% to 16.9% and 3.0% to 
9.5%, respectively. The biochemical analyses were performed at 
the laboratory of Bevital AS (Bergen, Norway; http://bevital.
no). We did not detect any significant correlations between 
metabolite levels and storage time using Spearman rank order 
correlations (data not shown).
Statistics
Univariate differences between AD and LBD were assessed 
using t tests, Pearson χ2, and Mann-Whitney U tests for nor-
mal, categorical, and skewed variables, respectively. Metabolite 
concentrations were transformed to approximate normality 
using Tukey’s ladder of powers.31 A constant of one was added 
prior to logarithmic transformation for all metabolites with a 
minimum concentration below 1 to avoid an uneven spread of 
the data after logarithmic transformations. Associations 
between cognitive deterioration and neuropsychiatric symp-
toms over 5 years and baseline metabolite levels were examined 
in a multiprocess model or joint model. Of note, although 
patients underwent 5 annual follow-up examinations, there 
were occasional delays, and some patients were followed for 
6 years. The MMSE test scores were transformed by the square 
root of errors, √(30-MMSE), thereby higher values indicate 
poorer performance. The MMSE raw scores were right skewed 
toward higher scores, which is problematic in statistics, as 
transformations typically work best to obtain normality with 
left-skewed data. Thus, the reciprocal of MMSE (30 − MMSE) 
was calculated to obtain a right-skewed distribution of the 
number of errors committed by patients on the MMSE (an 
MMSE score of 24 is 30 − 24 = 6 errors). After this, the square 
root transformation of the MMSE errors resulted in an approx-
imately normal distribution as assessed by quantile-quantile 
plots and histograms.32 However, 37 measurements of the 
transformed MMSE test scores reached a ceiling effect. Thus, 
right censoring was implemented using a linear mixed-effects 
Tobit model with random intercepts and slopes.
The NPI total score was best fitted using a negative bino-
mial random intercept model, according to the Bayesian 
information criterion. Random slopes could not be fitted, 
likely due to considerable individual deviation from a linear 
slope. The MMSE and NPI total models were linked by cor-
related random effects, implemented using a generalized 
structural equation model framework (Stata 15 package 
“gsem”). Each metabolite measured at baseline was entered in 
a separate multiprocess model, with years in study (time), age, 
age*time interaction, sex, AD vs LBD, AD vs LBD*time 
interaction, current smoking, glomerular filtration rate, and 
PLP as independent variables in the MMSE model. The 
independent variables were the same in the NPI total model, 
without a nonsignificant age*time interaction. Nonlinearity 
was checked using orthogonal polynomials of the trans-
formed metabolite levels.
Post hoc, we compared the multiprocess models stratified by 
diagnosis. We further assessed the association between metab-
olite concentrations and the presence of individual NPI items 
(domain score ⩾1) using a logistic random intercept model 
with time, age, sex, AD vs LBD, AD vs LBD*time interaction, 
current smoking, glomerular filtration rate, and PLP as inde-
pendent variables. Finally, all study findings were adjusted for 
multiple comparisons, using the tail area–based false discovery 
rate (FDR) due to dependency, and adjusted P values are 
reported (Q values or Q). This was done separately for post hoc 
tests (R package: fdrtool).33,34 The statistical analyses, besides 
FDR correction, were conducted in Stata (version 15; 
StataCorp, College Station, TX, USA).
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Ethics
The Regional Committee for Medical and Health Research 
Ethics approved the study protocol and a notification of change 
relating to biomarker analyses (REC number: 2010/633). All 
participants provided signed informed consent at baseline after 
a detailed explanation of the procedures.
Results
Study participants
The study included 155 patients (56% women) with 
dementia (90 AD, 65 LBD). The baseline mean MMSE 
score was 23.7 and mean educational level was 9.7 years. A 
total of 20% of the patients were current smokers at base-
line (Table 1).
Kynurenines and cognitive performance
Kynurenine measured at baseline had a significant nonlinear, 
quadratic, relationship with the average MMSE score over the 
5 follow-up examinations (Table 2, Figure 2), but not with the 
rate of change. Using orthogonal polynomials, the first polyno-
mial of kynurenine, representing a linear relationship, was not 
significant (estimate [Est.] −0.023, Q = 0.840), whereas the sec-
ond, representing a nonlinear relationship, was significant (Est. 
0.10, Q = 0.035).
Table 1. Participant demographics of the Dementia Study of Western Norway and serum metabolite concentrations at baseline.
CLINICAL CHARACTERISTICS DEMENTIA (N = 155) AD (N = 90) LBD (N = 65) P VALUE
Age, y, mean (SD) 75.1 (7.31) 75.1 (7.8) 75.1 (6.3) .694a
Education, y, mean (SD) 9.7 (3.0) 9.7 (3.1) 9.6 (2.8) .738a
Female, % 56.1 67.8 40.0 .001b*
Lewy body disease, % 42.3  
Current smokers, % 20.0 23.3 15.4 .222b
MMSE, score, mean (SD) 23.7 (2.8) 23.6 (2.5) 23.8 (3.1) .597a
GFRc, mean (SD) 79.2 (20.4) 79.2 (22.4) 80.7 (25.4) .459a
METABOLITES
Trpd,e 66.2 (22.4) 66.0 (22.8) 66.6 (15.5) .547f
Kynd,e 1.74 (0.67) 1.74 (0.58) 1.74 (0.73) .582f
HKe,g 50.0 (33.7) 48.0 (28.8) 54.4 (34.3) .033f*
KAe,g 51.1 (24.4) 51.5 (21.7) 50.2 (25.8) .772f
XAe,g 12.3 (9.0) 12.5 (8.9) 12.3 (9.9) .558f
AAe,g 21.7 (10.7) 20.1 (11.5) 22.5 (8.6) .539f
HAAe,g 36.1 (16.5) 35.2 (16.2) 39.2 (16.3) .360f
PICe,g 35.9 (22.4) 33.0 (18.0) 38.1 (26.5) .143f
QAe,g 474 (312) 465 (312) 481 (309) .736f
KTRe 2.59 (1.06) 2.49 (1.02) 2.69 (0.96) .244f
KKRe 7.97 (0.43) 8.00 (0.40) 7.95 (0.41) .357f
Neopte,g 19.7 (14.0) 18.7 (11.3) 20.6 (15.3) .276f
PLPe,g 31.6 (33.9) 34.0 (33.7) 29.6 (24.9) .021f*
Abbreviations: AA, anthranilic acid; AD, Alzheimer’s disease; GFR, glomerular filtration rate; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; KA, kynurenic 
acid; KTR, kynurenine-to-tryptophan ratio; Kyn, kynurenine; LBD, Lewy body dementia; MMSE, Mini-Mental State Examination; Neopt, neopterin; PIC, picolinic acid; PLP, 
pyridoxal 5´-phosphate; Trp, tryptophan; QA, quinolinic acid; XA, xanthurenic acid.
aStudent t test.
bPearson χ2 test.
cMetabolite levels in median and interquartile range.
dMicromoles per liter.
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Kynurenines and neuropsychiatric symptoms
The kynurenic acid-to-kynurenine ratio was positively associ-
ated with the rate of change per year in neuropsychiatric symp-
toms, specifically with more neuropsychiatric symptoms over 
time (Q = 0.045; see Figure 3). There was a trend for KA and 
XA to also be positively associated with more neuropsychiatric 
symptoms over time, but these findings were not significant 
after adjustment for multiple comparisons (Table 2).
Post hoc analyses
Differences in prognostic associations of kynurenines between AD 
and LBD. The associations between the kynurenines, cogni-
tive prognosis, and neuropsychiatric symptoms over 5 years did 
not differ between AD and LBD after corrections for multiple 
comparisons (no significant interaction by clinical diagnosis 
[AD versus LBD]; Supplementary Table 1, and Supplemen-
tary Figure 1).
Individual neuropsychiatric symptoms. The kynurenic acid-to-
kynurenine ratio was significantly associated with an increasing 
probability of hallucinations over time (odds ratios in Figure 4 
indicate increased odds per year), whereas KA was significantly 
associated with more hallucinations, on average, over 5 years 
(Q < 0.001) with no change over time. There were several other 
observed trends. Of note, KA, KKR, and XA displayed trends 
for increasing agitation over time. Kyn, AA, QA, neopterin, 
and KTR showed trends for association with reduced average 
test scores on the item for irritability, whereas Trp, Kyn, HK, 
and neopterin displayed trends for association with higher 
average probabilities of experiencing apathy (Figure 4).
Discussion
In this study, Kyn had a nonlinear relationship with the partici-
pants’ average MMSE test performance over 5 years. This rela-
tionship suggests that both low and high levels of Kyn are 
associated with poorer MMSE test performance, as compared 
Table 2. Associations between serum kynurenines and neopterin at baseline and 5-year prognosis in dementia.a
COGNITIVE PERFORMANCE (MMSE) NEUROPSYCHIATRIC SYMPTOMS (NPI TOTAL SCORE)
 EST. SE P VALUE Q EST. SE P VALUE Q
Trp 0.059 0.044 .185 Trp 0.010 0.055 .852  
Kyn −0.023 0.052 .656 Kyn −0.036 0.065 .569  
Kyn2 0.102 0.030 .006* .046*  
AA −0.080 0.048 .096 AA −0.097 0.058 .099  
KA 0.072 0.057 .209 KA −0.049 0.087 .575  
 KA*T 0.051 0.022 .021* .080
HK −0.099 0.060 .099 HK −0.005 0.077 .950  
XA 0.017 0.050 .728 XA −0.101 0.077 .190  
 XA*T 0.051 0.021 .017 .075
HAA −0.004 0.048 .932 HAA 0.027 0.058 .636  
QA −0.014 0.052 .795 QA −0.087 0.063 .170  
PIC 0.011 0.045 .808 PIC 0.022 0.057 .701  
Neopt 0.023 0.050 .647 Neopt −0.086 0.060 .149  
KTR 0.023 0.051 .648 KTR −0.074 0.064 .247  
KKR 0.092 0.046 .046 .133 KKR −0.050 0.074 .501  
 KKR*T 0.063 0.021 .003 .045*
Abbreviations: AA, anthranilic acid; Est., estimate; GFR, glomerular filtration rate; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; KA, kynurenic acid; KKR, 
kynurenic acid-to-kynurenine ratio; KTR, kynurenine-to-tryptophan ratio; Kyn, kynurenine; Kyn2, second degree orthogonal polynomial of Kyn; MMSE, Mini-Mental State 
Examination; Neopt, neopterin; NPI, Neuropsychiatric Inventory; PIC, picolinic acid; PLP, pyridoxal 5´-phosphate; SE, standard error; Trp, tryptophan; Q, Q value; QA, 
quinolinic acid; XA, xanthurenic acid.
aGeneralized structural equation model linking 2 mixed models by their random effects: Model 1: Tobit mixed-effects model with MMSE as the outcome, measured at 
baseline and for 5 consecutive years. Model includes random intercepts and slopes. MMSE transformed to √(30 − MMSE). Model 2: Negative binomial mixed-effects 
model with NPI total (sum of items 1 through 10) measured at baseline and for 5 consecutive years. Model includes random intercepts. Link: Random intercepts and 
slopes of MMSE correlated with random intercepts of NPI total. Covariates: Time, age (also *time for MMSE), sex, Lewy body dementia vs Alzheimer disease (also 
*time), current smoking, GFR, and PLP as independent variables.
*P < .05 or Q < 0.05.
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with values around the mean. Kynurenine was not associated 
with the rate of MMSE decline over time. A higher KKR was 
significantly associated with increasing neuropsychiatric symp-
toms over time. In post hoc analyses, we found that KKR and 
KA were significantly associated with more hallucinations. The 
associations between the kynurenines, cognitive prognosis, and 
neuropsychiatric symptoms over 5 years did not differ between 
patients with AD or LBD. However, several trends were 
observed, which should be investigated in a study with statisti-
cal power for subgroup analyses.
Kynurenine showed a nonlinear association with average 
MMSE score over 5 years (Figure 2), but not with the rate of 
change. Previously, we observed a similar nonlinear trend 
between Kyn and cognitive function in a cohort of community-
dwelling older adults.21 This may suggest that a homeostatic 
level of Kyn around the mean value can be beneficial for cogni-
tive function. One might speculate that the lack of association 
between kynurenines and the rate of cognitive decline suggests 
that circulating kynurenines are not related to strong drivers of 
cognitive deterioration, such as synaptic loss35 and tau pathol-
ogy.36 Availability of precursors of neuroactive kynurenines 
which are linked to both nicotinamide adenosine dinucleotide 
(NAD+) metabolism9 and low-grade inflammation,13 could 
lead to cognitive differences that are stable throughout the 
disease course. Circulating Kyn, which crosses the blood- 
brain-barrier (BBB), may affect kynurenines in the brain, as 
both TDO and IDO converting Trp to Kyn have low activity 
in the brain.9 Furthermore, Kyn is induced by pro-inflamma-
tory cytokines, but notably also gives rise to metabolites that 
suppress inflammation, indicating a complex relationship.37 
There is ample evidence that IDO activation has a negative 
impact on cognitive function in rodent models4-7 and can exac-
erbate AD pathology in amyloid knock-in mice.5 However, it 
is less clear how IDO activity outside the brain relates to cog-
nitive function. Peripheral interferon alpha may increase both 
blood and CSF levels of Kyn.38 Kynurenine could be a marker 
of IFN-γ activity, but neopterin and KTR, which are more 
strongly related to IFN-γ induction,39,40 were not associated 
with cognitive function in older humans.21 Whereas high Kyn 
levels may signify inflammation,13 low levels may limit the 
availability of a key precursor of neuroactive kynurenines and 
perhaps NAD+.9 Deficiency of kynurenines may explain poor 
outcomes with low Kyn levels, by decreasing levels of NAD+ 
leading to neuronal degeneration in dementia. Reduced avail-
ability of NAD+ may impair the activity of the NAD+-
dependent enzymes, such as the sirtuins, resulting in 
accumulation of amyloid-beta plaques and tau tangles.41
A higher KKR was significantly associated with more neu-
ropsychiatric symptoms over time. A similar association was 
found in post hoc analysis, suggesting that KKR was related to 
hallucinations with a similar trend for delusions and disinhibi-
tion, indicative of psychotic symptoms. Kynurenic acid was 
significantly associated with hallucinations independent of 
time in post hoc analysis, with a similar trend for agitation. 
The NMDAR antagonism, a function of KA, is a known trig-
ger of psychosis,42 and KA is increased in the brain19 and CSF 
of patients with schizophrenia,43 making this finding intrigu-
ing. Increased KA levels, indicating higher kynurenine ami-
notransferase (KAT) activity, may produce symptoms of 
Figure 2. Nonlinear association between MMSE and kynurenine. Low 
levels of kynurenine are associated with more errors on the MMSE on 
average (intercept). At mean kynurenine levels, there is no association 
with MMSE, whereas high or low serum concentrations are associated 
with more average MMSE errors. The model was estimated as a 
multiprocess model together with a model for the NPI total score (see 
statistics). Of note, a constant of 1 was added to kynurenine prior to 
logarithmic transformation to avoid an uneven spread below and above a 
kynurenine level of 1, shifting the log (mean) from 0.55 to 1.02. MMSE 
indicates Mini-Mental State Examination; NPI, Neuropsychiatric 
Inventory.
Figure 3. Kynurenic acid-to-kynurenine ratio and neuropsychiatric 
symptoms. The graph shows how a change in 1 standard deviation of the 
transformed and standardized levels of KKR, the reciprocal of 1/√(KKR) 
is associated with an increase in neuropsychiatric symptoms over time, 
using a negative binomial random intercept model, adjusted for age, sex, 
current smoking, glomerular filtration rate, and PLP in the model for 
MMSE. KKR indicates kynurenic acid-to-kynurenine ratio; MMSE, 
Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.
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schizophrenia in experimental animals.44 In addition, mice 
with genomic deletion of the KAT II enzyme show improved 
cognitive function.45 Furthermore, KA may lead to decreased 
levels of the neurotransmitters glutamate,46 dopamine,47 and 
acetylcholine,48 and KA has been linked to elevated dopamin-
ergic activity in the brain.49 KKR might reflect the activity of 
peripheral KATs in the periphery. Notably, KATs also generate 
XA, which was associated at trend toward more neuropsychi-
atric symptoms over time, specifically, agitation in post hoc 
analyses. However, contrary to Kyn, KA does not cross the 
BBB, but is formed in the brain from Kyn catalyzed by KATs.50 
Accordingly, follow-up studies measuring CSF kynurenines 
would be highly informative. In addition, KA is an agonist for 
the aryl hydrocarbon receptor51,52 and is an antagonist of α7 
nicotinic acetylcholine receptors (α7nAChR), both implicated 
in schizophrenia.53,54
There were several nonsignificant associations in post hoc 
analyses indicating that in particular AA and QA, but also 
KTR, Kyn, and neopterin, could be associated with less irri-
tability and motor disturbances. It is interesting that 
increased concentrations of many of these metabolites may 
indicate metabolic flux away from KA. Reduced activity of 
KMO, linked to higher KA,55 has been shown in 
schizophrenia.56
Our study suggests that increased circulating KA and KKR, 
potentially related to KAT activity, could be biomarkers of an 
increased risk of neuropsychiatric symptoms in dementia. 
Furthermore, several direct and indirect effects of kynurenines 
on neurotransmitter receptors51-54 suggest the possibility of a 
potential role in the pathogenesis of such symptoms. There are 
several important regulators of the kynurenine pathway in the 
periphery, such as IFN-γ40 and interleukin 1β (IL-1β).57 
Furthermore, IL-1β can affect the activity of KAT.57 Thus, 
both clinical and experimental studies are needed to confirm 
and elaborate on our findings.
Strengths of the study include its longitudinal design with 
annual follow-up examinations until death, a low dropout 
rate among the participants and centralized laboratory analy-
ses of all metabolites. The main limitations are a relatively 
small sample size, use of nonfasting blood samples, lack of 
longitudinal measurements of kynurenines, and KKR might 
not accurately reflect KAT activity. Furthermore, we could 
Figure 4. Post hoc: neuropsychiatric symptoms and metabolites. The bubble diagram shows associations between individual neuropsychiatric symptoms 
over 5  years and metabolites assessed by logistic random intercept models. The KKR was significantly associated with an increasing probability of 
hallucinations over time, whereas KA was significantly associated with more hallucinations, on average, over 5  years. The analyses were adjusted for 
using the Benjamini-Hockberg procedure with a false discovery rate of 0.05, and Q values, representing adjusted P values, were estimated. The bubble 
sizes are proportional to −log10 P values. Odds ratios (ORs) are depicted inside bubbles with thin dark borders representing significant P values and thick 
dark borders representing significant Q values. Light blue coloring represents an OR of <1, whereas pink represents an OR >1. Odds ratios are stratified 
by color transparency as 0% (OR: 0.60-0.69/1.75-2.00), 20% (OR: 0.70-0.79/1.50-1.74), 40% (OR: 0.80-0.89/1.25-1.49), 60% (OR: 0.90-0.99, 1.00-1.24). 
AA indicates anthranilic acid; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; KA, kynurenic acid; KA*T, kynurenic acid interaction with time; 
KKR, kynurenic acid-to-kynurenine ratio; KKR*T, kynurenic acid-to-kynurenine ratio interaction with time; KTR, kynurenine-to-tryptophan ratio; Kyn, 
kynurenine; Neopt, neopterin; OR, odds ratio; PIC, picolinic acid; Trp, tryptophan; QA, quinolinic acid; XA, xanthurenic acid; XA*T, xanthurenic acid 
interaction with time.
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not conclude that the associations with cognition are con-
fined to patients with dementia, due to the absence of an age-
matched longitudinal control group. Our previous study on 
community-dwelling older adults indeed found a similar 
association between Kyn and cognitive function.21 
Kynurenines in the brain may mostly be derived from circu-
lating kynurenines with Kyn as the main precursor.3 Still, 
synthesis of the potentially neuroprotective KA is confined to 
astrocytes, whereas the potentially neurotoxic QA is synthe-
sized in microglia.3 Thus, our assessment of kynurenines in 
dementia is incomplete without measurements of CSF and/
or brain samples.
In summary, circulating Kyn concentrations around the 
mean level may be beneficial for cognitive function in patients 
with dementia. Serum Kyn concentrations which diverge from 
the mean in either direction (higher or lower) may be associ-
ated with poorer global cognitive function. We observed an 
association of KA and KKR with neuropsychiatric symptoms, 
which adds to existing literature suggesting a role of kynure-
nines in mental health.3
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